Allogene Therapeutics ALLO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's cash & equivalents?
- Allogene Therapeutics (ALLO) reported cash & equivalents of $40.6M in Q1 2026.
- How has Allogene Therapeutics's cash & equivalents changed year-over-year?
- Allogene Therapeutics's cash & equivalents decreased by 23.0% year-over-year, from $52.75M to $40.6M.
- What is the long-term trend for Allogene Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Allogene Therapeutics's cash & equivalents has grown at a -20.3% compound annual growth rate (CAGR), from $192.8M to $61.98M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.